The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Cidara Therapeutics | Common Stock | 171757107 | 6,300 | 1,640,514 | SH | SOLE | 1,640,514 | 0 | 0 | ||
ESSA Pharma | Common Stock | 29668H708 | 9,404 | 1,709,848 | SH | SOLE | 1,709,848 | 0 | 0 | ||
FibroGen | Common Stock | 31572Q808 | 5,603 | 130,646 | SH | SOLE | 130,646 | 0 | 0 | ||
Gossamer Bio | Common Stock | 38341P102 | 95,645 | 6,119,345 | SH | SOLE | 6,119,345 | 0 | 0 | ||
Immunic | Common Stock | 4525EP101 | 13,303 | 1,371,494 | SH | SOLE | 1,371,494 | 0 | 0 | ||
Jounce Therapeutics | Common Stock | 481116101 | 4,627 | 529,965 | SH | SOLE | 529,965 | 0 | 0 | ||
Morphic Holding | Common Stock | 61775R105 | 50,958 | 2,969,582 | SH | SOLE | 2,969,582 | 0 | 0 | ||
ObsEva | Common Stock | H5861P103 | 3,818 | 999,364 | SH | SOLE | 999,364 | 0 | 0 | ||
Paratek Pharmaceuticals | Common Stock | 699374302 | 10,480 | 2,600,410 | SH | SOLE | 2,600,410 | 0 | 0 | ||
Pieris Pharmaceuticals | Common Stock | 720795103 | 2,718 | 750,741 | SH | SOLE | 750,741 | 0 | 0 | ||
Prevail Therapeutics | Common Stock | 74140Y101 | 10,589 | 668,907 | SH | SOLE | 668,907 | 0 | 0 | ||
Replimune Group | Common Stock | 76029N106 | 76,142 | 5,323,455 | SH | SOLE | 5,323,455 | 0 | 0 | ||
Translate Bio | Common Stock | 89374L104 | 19,842 | 2,437,603 | SH | SOLE | 2,437,603 | 0 | 0 | ||
Trevi Therapeutics | Common Stock | 89532M101 | 4,738 | 1,263,408 | SH | SOLE | 1,263,408 | 0 | 0 |